Complete and partial remission as surrogate end points in membranous nephropathy

Journal of the American Society of Nephrology

Volumn 26, Issue 12, 2015, Pages 2930-2937

  Thompson, Aliza ^a   Cattran, Daniel C ^b   Blank, Melanie ^a   Nachman, Patrick H ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; END STAGE RENAL DISEASE; EVALUATION STUDY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY INJURY; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; REMISSION; UNITED STATES; ANIMAL; BIOASSAY; COMPLICATION; GLOMERULONEPHRITIS, MEMBRANOUS; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; URINE;

BIOLOGICAL MARKER;

ANIMALS; BIOMARKERS; DISEASE PROGRESSION; ENDPOINT DETERMINATION; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84958254256     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015010091     Document Type: Article

References (41)

1. Erwin DT, Donadio JV Jr., Holley KE: The clinical course of idiopathic membranous nephropathy. Mayo Clin Proc 48: 697-712, 1973
2. Gluck MC, Gallo G, Lowenstein J, Baldwin DS: Membranous glomerulonephritis. Evolution of clinical and pathologic features. Ann Intern Med 78: 1-12, 1973
3. Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan Toronto Glomerulonephritis Registry: The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4: 1417-1422, 2009
4. Cattran DC: Management of membranous nephropathy. Minerva Urol Nefrol 54: 19-27, 2002
5. Noel LH, Zanetti M, Droz D, Barbanel C: Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 66: 82-90, 1979
6. Davison AM, Cameron JS, Kerr DN, Ogg CS, Wilkinson RW: The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 22: 61-67, 1984
7. MacTier R, Boulton Jones JM, Payton CD, McLay A: The natural history of membranous nephropathy in the West of Scotland. Q J Med 60: 793-802, 1986
8. Donadio JV Jr., Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 33: 708-715, 1988
9. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J AmSocNephrol 21: 697-704, 2010
10. Besarab A, Goodkin DA, Nissenson AR; Normal Hematocrit Cardiac Trial Authors: The normal hematocrit study-follow-up. N Engl J Med 358: 433-434, 2008
11. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
12. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemiawith epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
13. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
14. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P, Remuzzi G: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins.Am J Kidney Dis 26: 934-941, 1995
15. Zoja C, Benigni A, Remuzzi G: Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 7: 420-428, 1999
16. Yard BA, Chorianopoulos E, Herr D, van der Woude FJ: Regulation of endothelin-1 and transforming growth factor-beta1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 16: 1769-1775, 2001
17. Wang Y, Rangan GK, Tay YC, Wang Y, Harris DC: Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor kappaB in proximal tubule cells. J Am Soc Nephrol 10: 1204-1213, 1999
18. TangS, LeungJC, AbeK,ChanKW, Chan LY, Chan TM, Lai KN: Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 111: 515-527, 2003
19. Gaarkeuken H, SiezengaMA, Zuidwijk K, van Kooten C, Rabelink TJ, Daha MR, Berger SP: Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol 295: F1397-F1403, 2008
20. Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G: Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 45: 451-460, 1994
21. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17: 2974-2984, 2006
22. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, Troyanov S; Genes, Gender and Glomerulonephritis Group: The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23: 2247-2253, 2008
23. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960-966, 1992
24. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, Bizzari D, Banfi G: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
25. Hogan SL,Muller KE, Jennette JC, Falk RJ: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25: 862-875, 1995
26. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, SasdelliM, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl JMed 320: 8-13, 1989
27. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, SasdelliM, Pasquali S, PozziC, PiccoliG, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, FarinaM, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.JAmSoc Nephrol 9: 444-450, 1998
28. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
29. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P: A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47: 233-240, 2006
30. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004
31. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa: Tacrolimus monotherapy in membranous nephropathy:Arandomized controlled trial. Kidney Int 71: 924-930, 2007
32. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroidresistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
33. Ponticelli C, Passerini P, Altieri P, Locatelli F, Pappalettera M: Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 7[Suppl 1]: 85-90, 1992
34. Laluck BJ Jr., Cattran DC: Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 33: 1026-1032, 1999
35. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Maras M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416-1425, 2012
36. Caro J, Gutiérrez-Solís E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos MA, Perea L, Juárez GF, Ocaña J, Arroyo D, Goicoechea M, Fernández L, Oliet A, Hernández Y, Romera A, Segarra A, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN): Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant 30: 467-474, 2015
37. Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N, Perna A: Immunosuppression for membranous nephropathy: A systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 8: 787-796, 2013
38. Ponticelli C, Zucchelli P, Passerini P, Cesana B; The Italian Idiopathic Membranous Nephropathy Treatment Study Group: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 327: 599-603, 1992
39. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946-950, 1984
40. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
41. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, JayneDR,O'DonoghueD, Boulton-JonesM, Mathieson PW: Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial. Lancet 381: 744-751, 2013